Remedy Meds, LLC, a consumer-focused virtual care and pharmacy platform, has announced that it has entered into a definitive agreement to acquire Thirty Madison, Inc. in an all-stock deal valued at just over $500 million. The transaction is expected to close in the fourth quarter of 2025, subject to customary regulatory approvals, and is designed to create one of the most comprehensive multi-brand telehealth ecosystems in the country. By bringing together complementary services and trusted consumer brands, the companies intend to expand access to affordable, high-quality care across a wide range of conditions while accelerating growth through scale and integration.
Thirty Madison has established itself as a leading provider of virtual specialty care, known for delivering tailored treatment to patients with chronic and lifestyle-related conditions. Remedy Meds has built a rapidly growing platform focused on weight loss and metabolic health, combining telemedicine with an advanced pharmacy network to provide personalized care and medication fulfillment. Uniting these strengths will create a significantly larger, consumer-centric telehealth business serving patients across women’s health, men’s health, migraine management, weight loss, and other high-impact therapeutic areas.
The merged platform will bring together brands including Remedy Meds for weight management, Keeps for men’s hair loss, Nurx for women’s health, and Cove for migraine care. Each brand has earned consumer trust within its category, and together they will enable cross-category engagement, stronger retention, and improved care pathways. Patients will benefit from nationwide clinician coverage, streamlined insurance support, and a vertically integrated pharmacy operation capable of providing same-day video consultations, rapid prescription review, personalized treatment plans, and direct-to-door medication delivery.
From a business perspective, the strategic combination is intended to create scale and financial durability. Remedy Meds currently generates more than $450 million in annual revenue with strong profitability, while Thirty Madison’s profitable business exceeds $220 million. By aligning infrastructure, marketing channels, and patient acquisition strategies, the combined company expects to increase operating efficiency, reduce time to treatment, and sustain robust growth across its expanding service lines.
Haris Memon, Founder and CEO of Remedy Meds, emphasized that integrating Thirty Madison’s trusted brands with Remedy’s acquisition engine, retention programs, and pharmacy fulfillment capabilities represents an opportunity to broaden patient access and enhance clinical outcomes without sacrificing the fiscal discipline that has characterized the company’s trajectory. This unified approach positions the new entity as one of the largest direct-to-consumer virtual care and pharmacy networks, capable of meeting patients wherever they are while simplifying the path from diagnosis to treatment.
Click here to read the original news story.